Checkpoint Therapeutics inc (CKPT) - News Archive

UNLOXCYT: A New Horizon in the Management of Advanced Cutaneous Squamous Cell Carcinoma CSIMarket.com The recent approval of UNLOXCYT (cosibelimab-ipdl) by the U.S. Food and Drug Administration (FDA) marks a significant...

A Glimpse into the Future: Checkpoint Therapeutics Cosibelimab Shows Promise in Advanced Cutaneous Squamous Cell CarcinomaIn an era where scientific innovation meets clinical need, Checkpoint Therapeutics has unveiled p...

GC Cell and Checkpoint Therapeutics Join Forces for Combined Cancer ResearchIn a groundbreaking collaboration, GC Cell and Checkpoint Therapeutics have announced their partnership to pave the way for new advancements in...

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWALTHAM, Mass., July 02, 2024 - Checkpoint Therapeutics, Inc. (Checkpoint) (Nasdaq: CKPT), a clinical-stage...

Checkpoint Therapeutics, a clinical-stage immunotherapy and targeted oncology company, has recently announced that it has completed the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug A...

Checkpoint Therapeutics, a clinical-stage immunotherapy and targeted oncology company, has recently reached a significant milestone in its pursuit of a biologics license application (BLA) for cosibelimab. The company ha...

Legal Developments in Pharmaceutical Investment: A Detailed Examination of the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. The pharmaceutical industry, known for its potential high rewards, is also fraugh...

CKPT Shareholder Alert: Rosen Law Firm Advises Checkpoint Therapeutics Investors to Seek Legal Counsel Before June 4th Deadline in Securities Class ActionThe renowned Rosen Law Firm, a globally recognized investor right...

Checkpoint Therapeutics Inc., a clinical-stage immunotherapy and targeted oncology company, has recently made an exciting announcement regarding its latest financial development. The company has officially entered into...

In a recent development, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for cosibelimab, a promising drug under development for a range of medical conditions, including certain t...